

(This document is an English translation of the original Japanese document. If there are any discrepancies between this document and the original Japanese document, the original Japanese document prevails.)



February 26, 2026

Company name: Hodogaya Chemical Co., Ltd.
Name of representative: Yuto Matsumoto,
President and Representative Director
(Securities code: 4112, Prime Market of
Tokyo Stock Exchange)
Inquiries: Hideaki Hashizume,
Executive Officer & General Manager
Corporate Planning Department
(Telephone: +81-3-6852-0327)

Notice Concerning Collaboration with YUKI GOSEI KOGYO CO., LTD. (Securities Code: 4531) and Share Acquisition Corresponding to the Accumulation of Shares

Hodogaya Chemical Co., Ltd. (hereinafter the "Company" or "HCC") has reached an agreement with YUKI GOSEI KOGYO CO., LTD. (Securities Code: 4531; Headquarters: Chuo-ku, Tokyo; hereinafter referred to as the "YGK") to commence collaboration in the nucleic acid therapeutics CDMO (Contract Development and Manufacturing Organization) business.

Furthermore, for the purpose of strongly promoting this collaboration and building a long-term relationship with YGK, the Company will acquire 1,098,700 shares of YGK (5.08% of total voting rights) through a purchase via the Tokyo Stock Exchange's off-auction trading system (ToSTNeT-1), as detailed below.

Please note that this share acquisition falls under the "act of purchase specified by Cabinet Order as being equivalent to a tender offer" pursuant to Article 167, Paragraph 1 of the Financial Instruments and Exchange Act and Article 31 of the Order for Enforcement of the Financial Instruments and Exchange Act. The details are as follows.

1. Purpose of the Collaboration

Nucleic acid therapeutics, which use oligonucleotides as their basic framework, are attracting significant attention as next-generation pharmaceuticals effective against hereditary diseases, rare diseases, and cancers that have been difficult to treat with conventional small-molecule or antibody drugs.

In the biomaterial field, HCC group, through its consolidated subsidiary SFC CO., LTD. (South Korea; hereinafter "SFC"), has been developing proprietary raw materials and conducting contract synthesis for research-grade/non-GMP oligonucleotides. The group's strengths lie in its high agility in small-batch, high-variety production and its established manufacturing infrastructure.

YGK, through its extensive experience in small-molecule drug manufacturing, possesses advanced manufacturing and quality control systems compliant with GMP standards, as well as deep expertise in the production of nucleic acid-related compounds.

Through this collaboration, we aim to integrate the strengths of both companies to provide one-stop solutions—covering everything from raw materials to GMP manufacturing—to global stakeholders, including academia and pharmaceutical companies.

Furthermore, this initiative embodies the "strategic move into the nucleic acid therapeutics field" set forth in the Hodogaya Chemical group's "Vision for 2030" (to be announced in May 2026 as part of the next Mid-term Management Plan). We position this as a key strategic measure for achieving non-linear growth for the Group.

2. Details of the Share Acquisition

The Company plans to acquire a total of 1,098,700 common shares of YGK held by existing shareholders through ToSTNeT-1.

3. Overview of YGK

Name	YUKI GOSEI KOGYO CO., LTD.		
Address	10-4, Nihonbashi-Ningyocho 3-chome, Chuo-ku, Tokyo		
Representative	Seiichiro Matsumoto, Representative Director, President and CEO		
Business Description	<ul style="list-style-type: none"> • Manufacturing and sales of organic synthetic products and general chemical products • Manufacturing and sales of pharmaceuticals, quasi-drugs, veterinary drugs, food, food additives, feed additives, industrial chemicals, fragrances, and cosmetics • Sales of raw materials and products related to the items listed above 		
Capital	3,471 million yen		
Date of Establishment	November 4, 1947		
Major Shareholders and Shareholding Ratio (Top 5, as of Sept 30, 2025)	Nipro Corporation	15.25%	
	Nagase & Co., Ltd.	5.08%	
	Taiho Pharmaceutical Co., Ltd.	3.11%	
	MUFG Bank, Ltd.	3.08%	
	The Joyo Bank, Ltd.	2.84%	
Relationship with the Company	Capital Relationship: Not applicable. Personnel Relationship: Not applicable. Business Relationship: Not applicable.		
Financial Results and Condition of YGK (million yen)			
Fiscal Year End	FY 2023	FY 2024	FY 2025
Net Sales	12,839	12,932	15,128
Operating Profit	897	1,125	1,216
Ordinary Profit	660	1,130	1,139
Net Profit	556	776	896
Net Assets	11,478	12,430	13,106
Total Assets	22,118	24,370	26,871
Earnings per Share (Yen)	25.51	35.57	41.40
Net Assets per Share (Yen)	525.98	569.60	608.38
Dividends per Share (Yen)	7.00	8.00	9.00

4. Outline of the Share Acquisition

1. Subject Shares	YUKI GOSEI KOGYO CO., LTD.
2. Security Code	4531
3. Shares to be Acquired	1,098,700 Shares
4. Percentage of voting rights	5.08%
5. Expected Date of the Share Acquisition	February 27, 2026

5. Future Outlook

The impact of this matter on the Company's consolidated financial results is expected to be immaterial. Should any matters arise that require disclosure in the future, the Company will announce them promptly.

End of document